Novo Nordisk asks the FDA to add Semaglutide to the Demonstrably Difficult to Compound list.

FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of some of these peptides.

by | Oct 14, 2024 | Anti-Aging News, Sterile & Non-Sterile Compounding

The FDA stirred enormous controversy when, without much notice, they placed some of the most popular peptides on their category 2 list, which disallows the compounding with these bulk substances also known as (APIs) Active Pharmaceutical Ingredients. Many of the...